Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Vertex Pharmaceuticals Incorporated

NASDAQ

Market Cap.

117.92B

Avg. Volume

1.04M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Vertex Pharmaceuticals Incorporated!

Still processing it, give me a bit more time...

Vertex Pharmaceuticals Incorporated News

Vertex Pharmaceuticals Incorporated Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareBiotechnology
vrtx.com

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated Earnings & Revenue

Vertex Pharmaceuticals Incorporated Financials

Table Compare

Compare VRTX metrics with:

   

Earnings & Growth

VRTX

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

VRTX

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

VRTX

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

VRTX

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Vertex Pharmaceuticals Incorporated Income

Vertex Pharmaceuticals Incorporated Balance Sheet

Vertex Pharmaceuticals Incorporated Cash Flow

Vertex Pharmaceuticals Incorporated Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioSell
Price/Earnings RatioBuy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Vertex Pharmaceuticals Incorporated Executives

NameRole
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating Officer
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial Officer
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman
NameRoleGenderDate of BirthPay
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director19735.59M
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating OfficerMale19662.76M
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer19652.17M
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial OfficerMale19682.12M
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman195695.02K

Vertex Pharmaceuticals Incorporated Insider Trades

Date22 May
NameSACHS BRUCE I
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares7073
Date22 May
NameSACHS BRUCE I
RoleDirector
TransactionDisposed
TypeS-Sale
Shares7073
Date22 May
NameSACHS BRUCE I
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares7073
Date20 May
NameKewalramani Reshma
RoleCEO & President
TransactionDisposed
TypeS-Sale
Shares15202
Date15 May
NameSachdev Amit
RoleEVP Chief Patient & Ext Af Off
TransactionDisposed
TypeS-Sale
Shares32
DateNameRoleTransactionTypeShares
22 MaySACHS BRUCE IDirectorAcquiredM-Exempt7073
22 MaySACHS BRUCE IDirectorDisposedS-Sale7073
22 MaySACHS BRUCE IDirectorDisposedM-Exempt7073
20 MayKewalramani ReshmaCEO & PresidentDisposedS-Sale15202
15 MaySachdev AmitEVP Chief Patient & Ext Af OffDisposedS-Sale32

Discover More

Streamlined Academy

Vertex Pharmaceuticals Incorporated

NASDAQ

Market Cap.

117.92B

Avg. Volume

1.04M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Vertex Pharmaceuticals Incorporated News

Vertex Pharmaceuticals Incorporated Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Vertex Pharmaceuticals Incorporated Earnings & Revenue

Vertex Pharmaceuticals Incorporated Income

Vertex Pharmaceuticals Incorporated Balance Sheet

Vertex Pharmaceuticals Incorporated Cash Flow

Vertex Pharmaceuticals Incorporated Financials Over Time

Vertex Pharmaceuticals Incorporated Executives

NameRole
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating Officer
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial Officer
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman
NameRoleGenderDate of BirthPay
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director19735.59M
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating OfficerMale19662.76M
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer19652.17M
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial OfficerMale19682.12M
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman195695.02K

Vertex Pharmaceuticals Incorporated Insider Trades

Date22 May
NameSACHS BRUCE I
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares7073
Date22 May
NameSACHS BRUCE I
RoleDirector
TransactionDisposed
TypeS-Sale
Shares7073
Date22 May
NameSACHS BRUCE I
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares7073
Date20 May
NameKewalramani Reshma
RoleCEO & President
TransactionDisposed
TypeS-Sale
Shares15202
Date15 May
NameSachdev Amit
RoleEVP Chief Patient & Ext Af Off
TransactionDisposed
TypeS-Sale
Shares32
DateNameRoleTransactionTypeShares
22 MaySACHS BRUCE IDirectorAcquiredM-Exempt7073
22 MaySACHS BRUCE IDirectorDisposedS-Sale7073
22 MaySACHS BRUCE IDirectorDisposedM-Exempt7073
20 MayKewalramani ReshmaCEO & PresidentDisposedS-Sale15202
15 MaySachdev AmitEVP Chief Patient & Ext Af OffDisposedS-Sale32

Streamlined Academy

Website screenshot
HealthcareBiotechnology
vrtx.com

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Vertex Pharmaceuticals Incorporated!

Still processing it, give me a bit more time...

Vertex Pharmaceuticals Incorporated Financials

Table Compare

Compare VRTX metrics with:

   

Earnings & Growth

VRTX

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

VRTX

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

VRTX

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

VRTX

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Vertex Pharmaceuticals Incorporated Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioSell
Price/Earnings RatioBuy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More